Virtu Financial LLC Acquires New Stake in Kymera Therapeutics, Inc. $KYMR

Virtu Financial LLC bought a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the 4th quarter, Holdings Channel reports. The institutional investor bought 27,283 shares of the company’s stock, valued at approximately $2,123,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Baker BROS. Advisors LP boosted its stake in Kymera Therapeutics by 30.2% in the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after purchasing an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC lifted its position in Kymera Therapeutics by 17.7% in the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after acquiring an additional 1,124,747 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after purchasing an additional 1,061,957 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after purchasing an additional 845,922 shares in the last quarter. Finally, Holocene Advisors LP bought a new position in Kymera Therapeutics during the 3rd quarter valued at about $47,563,000.

Insider Buying and Selling

In other Kymera Therapeutics news, Director Elena Ridloff sold 3,000 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $87.00, for a total transaction of $261,000.00. Following the completion of the sale, the director directly owned 3,000 shares of the company’s stock, valued at approximately $261,000. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Bruce Booth sold 5,900 shares of the business’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $89.96, for a total transaction of $530,764.00. Following the transaction, the director owned 5,641 shares of the company’s stock, valued at approximately $507,464.36. This trade represents a 51.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 234,357 shares of company stock valued at $19,072,496. Company insiders own 15.98% of the company’s stock.

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock opened at $90.43 on Friday. The stock’s fifty day moving average price is $83.16 and its 200-day moving average price is $80.96. The firm has a market cap of $7.44 billion, a P/E ratio of -25.33 and a beta of 2.02. Kymera Therapeutics, Inc. has a 12 month low of $36.65 and a 12 month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.18. The firm had revenue of $34.37 million during the quarter, compared to analysts’ expectations of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company’s revenue was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.82) EPS. Analysts forecast that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. BTIG Research cut their price target on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Canaccord Genuity Group assumed coverage on Kymera Therapeutics in a research note on Wednesday, May 6th. They issued a “buy” rating and a $106.00 price objective for the company. Brookline Capital Markets reaffirmed a “buy” rating on shares of Kymera Therapeutics in a research note on Monday, June 8th. Morgan Stanley reiterated an “overweight” rating and issued a $119.00 target price on shares of Kymera Therapeutics in a report on Thursday, April 30th. Finally, Jefferies Financial Group assumed coverage on shares of Kymera Therapeutics in a research note on Monday, March 16th. They issued a “buy” rating and a $110.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $117.14.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.